Article
Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA.
The Journal of investigative dermatology - 1 Feb 2008
Oldenburg Reid P, Liu Monica S, Kolodney Michael S
Abstract excerpt
Detection of mutated genomic DNA from cancer cells circulating in blood may improve tumor staging and patient selection for targeted therapy. However, the task of detecting a few mutated cells in the presence of a large excess of wild-type cells requires a sensitive and selective assay. We describe a novel approach to detect circulating melanoma cells harboring a common point mutation in the BRAF kinase. In the...
Topics
- Biomarkers, Tumor
- Cell Line
- DNA Primers
- DNA, Neoplasm
- Genetic Testing
- Humans
- Keratinocytes
- Melanoma
- Mutation
- Nucleic Acid Amplification Techniques
- Oligonucleotides
